Medical News |
| Aflibercept reduces ovarian ascites but carries bowel perforation risk Posted: 28 Dec 2011 04:00 PM PST The vascular endothelial growth factor inhibitor aflibercept significantly reduces malignant ascites in women with ovarian cancer but carries a risk for fatal bowel perforation, results of a phase II, placebo-controlled trial show. |
| You are subscribed to email updates from MedWire Medical News Combined Feed To stop receiving these emails, you may unsubscribe now. | Email delivery powered by Google |
| Google Inc., 20 West Kinzie, Chicago IL USA 60610 | |
No comments:
Post a Comment